Tag: Cardium TherapeuticsSort
Cardium Therapeutics Generx Presentation January 2013
Cardium Therapeutics Wins Patents Rights, Settles Competition with Boston Scientific
EC Approval of Glybera A Significant Industry Milestone in Gene Therapy
Commenting on the October 25 approval by the European Commission for its gene therapy, Glybera®, Dutch biotech company uniQure said Monday it plans to start selling Glybera in Europe by mid-2013 and predicted a boom of similar therapies. The EC approval marks Glybera as the first gene therapy to be approved in the Western world.
“We believe that after Glybera’s approval gene therapy is at the beginning of a period of rapid growth similar to the development of the antibody business in the last decade,” said Joern Aldag, Chief Executive Officer at uniQure.
Cardium Therapeutics, Inc. (CXM) Acquisition of To Go Brands Further Taps Growing Supplements Market
Late in September, a comprehensive report by Global Industry Analysts, Inc. stated that the global nutraceutical market will cross $243 Billion by 2015, “owing to consumer desire for leading a healthy life and increasing scientific evidence supporting health foods.”
The research firm also attributes the strong growth rate to an aging population and rising healthcare costs as catalysts for the neutraceutical industry that it calls “one of the brightest spots in a global market suffering from its worst economic crisis.”
Cardium Therapeutics Investor Presentation with To Go Brands Acquisition
Updated Cardium Therapeutics (NYSE MKT: CXM) Investor Presentation including the acquisition of To Go Brands that was announced on October 1, 2012.
The link provided is for SlideShare. The presentation can also be found on the Cardium Therapeutics website at: http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations
Excellagen Presentation on Cardium Therapeutics Website
An updated presentation for Excellagen has been published on the Cardium Therapeutics (NYSE MKT: CXM) website. The pdf file is available for viewing/dowloading at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations.
Cardium Therapeutics Releases New Excellagen Case Studies
Cardium's Excellagen® Named As Top 10 Innovation In Podiatry
Cardium Therapeutics (NYSE MKT: CXM) today announced that its professional-use Excellagen® (formulated collagen gel 2.6%) wound care product was selected as one of the top ten podiatry innovations in 2012 by the publication Podiatry Today. The Company also announced that it will be introducing Excellagen at the American Podiatric Medical Association (APMA) National Meeting (Booth 1910) being held August 16 – 19, 2012 in Washington, DC.
Cardium CEO Discusses Generx, Excellagen and MedPodium with CEOCFOInterviews.com
Cardium Therapeutics Presents at Marcum MicroCap Conference 2012 Video
Christopher J. Reinhard, Chairman & CEO presented at the Marcum MicroCap Conference on June 20, 2012 at at the Roosevelt Hotel in New York City. In the presentation, Mr. Reinhard details Cardium products, including Generx as a product candidate for advanced coronary artery disease, Excellagen for wound care management and the company’s line of MedPodium neutraceuticals,metabolics and aesthetics.